- Home
- MSIF vs SION Comparison
MSIF vs SION Comparison
Compare MSIF & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSIF
- SION
- Stock Information
- Founded
- MSIF 2011
- SION 2019
- Country
- MSIF United States
- SION United States
- Employees
- MSIF N/A
- SION N/A
- Industry
- MSIF
- SION
- Sector
- MSIF
- SION
- Exchange
- MSIF NYSE
- SION NYSE
- Market Cap
- MSIF 795.9M
- SION 920.2M
- IPO Year
- MSIF N/A
- SION 2025
- Fundamental
- Price
- MSIF $16.20
- SION $20.47
- Analyst Decision
- MSIF Buy
- SION Strong Buy
- Analyst Count
- MSIF 5
- SION 1
- Target Price
- MSIF $18.50
- SION $32.00
- AVG Volume (30 Days)
- MSIF 85.1K
- SION 260.6K
- Earning Date
- MSIF 05-12-2025
- SION 08-25-2025
- Dividend Yield
- MSIF 8.90%
- SION N/A
- EPS Growth
- MSIF N/A
- SION N/A
- EPS
- MSIF 1.50
- SION N/A
- Revenue
- MSIF $134,105,000.00
- SION N/A
- Revenue This Year
- MSIF $9.98
- SION N/A
- Revenue Next Year
- MSIF $10.94
- SION N/A
- P/E Ratio
- MSIF $10.89
- SION N/A
- Revenue Growth
- MSIF N/A
- SION N/A
- 52 Week Low
- MSIF $14.01
- SION $7.26
- 52 Week High
- MSIF $18.10
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- MSIF N/A
- SION N/A
- Support Level
- MSIF N/A
- SION N/A
- Resistance Level
- MSIF N/A
- SION N/A
- Average True Range (ATR)
- MSIF 0.00
- SION 0.00
- MACD
- MSIF 0.00
- SION 0.00
- Stochastic Oscillator
- MSIF 0.00
- SION 0.00
About MSIF MSC INCOME FUND INC
MSC Income Fund Inc is a non-diversified closed-end management investment company. The investment objective is to generate current income through debt and equity investments and the secondary objective is to generate long-term capital appreciation through such investments. The company invests in senior secured term loans, second lien loans, and mezzanine debt and selected equity investments issued by lower middle-market and middle-market companies.
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.